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INTRODUCTION
Endometrial carcinoma is the most common malignant
tumor of the female genital tract in western country. Many
patients with endometrial carcinoma are in their 50’s and
only 5% of them are under age 40 (1). Endometrial adeno-
carcinoma in child bearing age is relatively uncommon,
except in those with obesity, chronic anovulation, irregular
menstruation, infertility and is associated with so-called poly-
cystic ovary syndrome or estrogen producing tumor. Pro-
longed unopposed estrogen exposure in infertile women with
chronic anovulation may induce endometrial hyperplasia
progressing to carcinoma. Failure of ovulation, characteristi-
cally expressed with amenorrhea or oligomenorrhea, occurred
in 21% of infertile patients, ovulatory dysfunction cause sub-
fertility in 15-20% of couples (2). The risk of endometrial
carcinoma was increased 4.8-folds in infertile patients and
10.3-folds in infertile women with chronic anovulation (3).
So it is essential to evaluate the endometrial disease thoroughly
during infertility work up in these patients (4, 5).
Most patients with endometrial carcinoma undergo hys-
terectomy, however, in a young woman who wishes to bear
a child, trial treatment with progestins has been attempted,
and successful pregnancies after the conservative treatment
have been reported. Endometrial cancer in younger patients
(age under the 40 yr) is generally associated with a better
prognosis because the tumors are detected at an early stage
and likely to be highly differentiated and hormonally depen-
dent. In such a setting, high dose progestins followed by
curettage may be the alternative treatment in patients who
wish to preserve fertility.
We report a case of successful live birth through the in vitro
fertilization (IVF) program after conservative treatment of
endometrial cancer (stage I, grade I).
CASE REPORT
A 36-yr-old woman visited in our infertility clinic, com-
plaining of primary infertility for 1 yr. Her menstrual cycle
was irregular, about 60-120 days, body mass index was 27.5
(body weight: 73 kg, height: 163 cm). She had a history of
explo-laparotomy due to endometriosis. Neither she nor any
other members of her family had diabetes or hypertension.
Abdomino-pelvic examination showed the unremarkable
findings and transvaginal ultrasonogram showed small uter-
ine myoma, 24-21 mm, normal contour of endometrium,
10 mm, and well defined normal both ovaries. Full infertility
work up was performed, results of semen analysis was nor-
mal, hormonal study (LH, FSH, Estradiol, Prolactin, TSH,
Testosterone, DHEA-S) showed normal findings except high
FSH level of 9.66 mIU/mL. The office endometrial aspira-
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A Successful Live Birth Through in vitro Fertilization Program After
Conservative Treatment of FIGO Grade I Endometrial Cancer 
Infertile women with chronic anovulation are prone to be exposed to unopposed
estrogen stimulation and have the high risk of being suffering from endometrial
hyperplasia or even endometrial carcinoma. A few reports have suggested that
nulliparous young women (under 40 yr of age) with endometrial carcinoma could
be treated conservatively to preserve fertility and succeed the live birth. We report
on a 36-yr-old woman who received conservative treatment of endometrial carci-
noma (stage I, grade 1) by curettage and progestin. After megestrol medication of
total 71,680 mg during 24 weeks, we found the regression of endometrial lesion by
curettage and hysteroscopic examination. Then we decided to perform in vitro ferti-
lization program. Two embryos were transferred and heterotypic pregnancy was
diagnosed 27 days after embryo transfer. After right salpingectomy, she received
routine obstetrical care and delivered by cesarean section at 38 weeks in gestational
periods. Two years after delivery, she is healthy without any evidence of recurrent
disease. The fertility preserving treatment is an option in endometrial cancer patients
if carefully selected, and assisted reproductive technologies would be helpful.
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Accepted : 15 June 2005tion biopsy showed secretory phase and finding of luteal phase
defect. Hysterosalpingogram revealed one point filling defect
in the uterine cavity and mild dilatation of ampullary por-
tion of Fallopian tubes, but good intraperitoneal spillage (Fig.
1A). On laparoscopic examination, peritubal adhesion was
detected and adhesiolysis was performed. On hysteroscopic
examination, there was a polypoid mass on fundal area and
hysteroscopic biopsy and curettage was done. The patholog-
ic evaluation of endometrial tissue revealed well differenti-
ated endometrial adenocarcinoma (Grade 1, Fig. 2A) with
positive estrogen and progesterone receptors. After curettage,
we confirmed that there was no detectable endometrial mass
or myometrial invasion or cervical involvement by MRI imag-
ing (Fig. 1B). Final diagnosis was primary infertility accom-
panying endometrial carcinoma, FIGO grade I without myo-
metrial invasion. 
After counseling, the patient wished to retain her ability
to conceive, so high dose progestin therapy was recommend-
ed. Oral megestrol acetate was prescribed 600 mg daily for 8
weeks. On follow-up hysteroscopic examination, she still
got a small protruding mass on fundal area. We performed
hysteroscopic biopsy and endometrial curettage. The patho-
logic evaluation of endometrium revealed complex hyper-
plasia without cellular atypia (Fig. 2B). She continued to
receive megestrol acetate but complained intolerable weight
gain from 73 to 88 kg. We decided to reduce the dose to
400 mg, daily for 4 weeks, then 320 mg, daily for 12 weeks.
After megestrol medication of total 71,680 mg during 24
weeks, we found smooth atrophic endometrium by hystero-
scopic examination, and this was confirmed as atrophic endo-
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Fig. 1. (A) Hysterosalpingogram shows a small filling defect in the
uterine cavity. (B and C) MRI reveals no residual tumor in the en-
dometrium nor myometrial involvement after curettage. 
A
C BIVF Program After Conservative Treatment of Endometrial Cancer 569
metrium through the histological examination of tissue ob-
tained by curettage. Then we decided to perform IVF pro-
gram in order to optimize the patient’s potential for fertility
and achieve a viable pregnancy without further delay.
After pituitary down-regulation by the GnRHa (Busere-
lin acetate, Superfact
�, Hoechst), follicle-stimulating hor-
mone preparation (Follimon
�, LGIC, Korea) was adminis-
trated, 375 IU daily for 12 days. The follicular growth was
monitored from gonadotropin day 5 by 3 days interval and
human chorionic gonadotropin (IVF-C
�, LGIC, Korea) 10,000
IU was administrated when the at least 3 or more follicles
reached 18 mm in diameter. And 35 hr later, oocytes aspira-
tion was performed under the guidance of transvaginal ultra-
sonography. Two mature oocytes were retrieved and insemi-
nated with her husband’s prepared spermatozoa. Fifty seven
hours after oocyte retrieval, the two high grade 4-cell embryos
were transferred. Measurement of  -hCG revealed 3,449
mIU/mL on 19 days after embryo transfer, and on 23 days
after embryo transfer, intrauterine single gestational sac with
yolk sac and right tubal pregnancy were identified by trans-
vaginal ultrasonogram. Right salpingectomy was performed
under the epidural anesthesia, on 27 days after embryo trans-
fer, we could detect the fetal pole with heart beat in the int-
rauterine gestational sac after that procedure. Then she received
routine obstetrical care and delivered by Cesarean section at
38 weeks in gestational periods. The baby was female, 2,590 g,
and the Apgar score was 8 at 1 min, 9 at 5 min. Placenta was
grossly and microscopically normal, there was no evidence of
residual tumor in the uterus and adnexa or abdominal organ.
Twelve weeks after delivery, endometrial thickness mea-
sured by transvaginal ultrasonography was 4 mm and endo-
metrial biopsy revealed no evidence of recurrent disease. Two
years after delivery, she was healthy without any evidence of
recurrent disease.
DISCUSSION
Endometrial carcinoma is the most common malignant
tumor of the female genital tract in western country. But in
Korea, endometrial carcinoma is the third frequent malig-
nant tumor of the female genital tract (10.4% of the female
genital tract) and only 13.5% of them are under age 40 yr,
but its incidence has been increasing steadily.
The standard therapy for endometrial carcinoma is staging
laparotomy with total abdominal hysterectomy and bilater-
al salpingo-oophorectomy, followed by adjuvant radiation
for patients judged to be at high risk for local recurrence.
Several lines of evidence have suggested that two different
pathogenic types of endometrial cancers exist according to
hyperestrogenic state or not. The type of endometrial cancer
associated with hyperestrogenism typically develops via a
characteristic sequence from hyperplastic lesion of the endo-
metrium to premalignant lesion, finally invasive cancer and
has tendency to be diagnosed in early stage, as low grade,
with estrogen and progesterone receptors (6). In such a set-
ting, conservative treatment with progestin may be the alter-
native treatment modality in patient who wishes to preserve
fertility (7).
In a case of series, three of eight patients with grade 1 ade-
Fig. 2. (A) A well-differentiated endometrioid adenocarcinoma. Light micrograph shows anaplastic proliferation of the endometrial glands
associated with foci of squamoid differentiation (H&E stain, ×200). (B) After progestin therapy for 8 weeks, the endometrium shows com-
plex hyperplasia without nuclear atypia in the dilated endometrial glands (H&E stain, ×200).
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nocarcinoma, limited to the endometrium, were successfully
treated with progesterone followed by dilatation and curet-
tage (8). A review of the pathology records at Johns Hopkins
Medical Center between 1990 and 1996 yield 12 patients
younger than 40 yr of age who had well-differentiated ade-
nocarcinoma of the endometrium were treated with progestin
alone for 3 to 18 months. Nine of 12 patients had regression
of lesion and remained free of disease at a mean follow up
duration of 40 months (9). Kim et al. also reported that pro-
gestin treatment for well-differentiated adenocarcinoma in
young women was successful in 13 out of 20 cases (10).
But no consensus exists about specific conservative treat-
ment for well-differentiated endometrial cancer, that is, the
dose and duration of progestins treatment have not yet been
established. The reported daily doses of progestins were vari-
able, from 40 mg to 400 mg of megestrol acetate or 200 mg
to 600 mg of medroxyprogesterone acetate, and the durations
of medication were from 3 months to 18 months (9-13).
The conservative therapy has apparent risks and some inves-
tigators have strongly opposed to use conservative treatment
because the treatment with progestins may not always achieve
remission (14). The risk of disease progression occurring dur-
ing or after progestin therapy would be approximately 5%
(8), while Randall and Kurman did not experience the patients
with progressive disease except patients with persistent lesions
(9).
Before the decision of conservative treatment, it is prereq-
uisite to know the depth of myometrial invasion and grade
of tumor cells, that is, conservative treatment is indicated
only in the case of well-differentiated, early stage disease with-
out extrauterine lesions. For these purposes, MRI would be
helpful for evaluation of invasion depth of tumor and detect-
ing extrauterine tumor and the endometrial biopsy should
be performed for grading of tumor. There were several reports
about inaccuracy of endometrial biopsy, incorrect diagnoses
of 28 percents were reported with office Novak curette biopsy
with 18% having a higher grade tumor in hysterectomy (15),
although the dilatation and curettage was more accurate than
office endometrial biopsy in predicting tumor grade, the dila-
tation and curettage also incorrectly graded approximately
25% of the patients, with higher grade tumor being missed
in about 10% (16). For the reduction of misdiagnosis, as addi-
tional diagnostic tool, hysteroscopic examination such as in
our case would be helpful.
After the conservative treatment of endometrial carcinoma,
the pregnancy rate was somewhat disappointing, that is, only
3 of 24 patients delivered viable infants (10). To permit sub-
sequent pregnancy as well as to prevent the recurrence of
disease, it is important to induce ovulation following regres-
sion of carcinoma. Given the high incidence of chronic anovu-
lation and infertility in young women with endometrial car-
cinoma, it is likely that trial of assisted reproductive technolo-
gies would have resulted in a higher pregnancy rate. Kimmig
et al. reported successful pregnancy achieved by gamete int-
rafallopian transfer and Pinto et al. reported successful preg-
nancy through the in vitro fertilization after controlled overi-
an hyperstimulation and recently Lowe et al. reported suc-
cessful pregnancy through the oocyte donation program (7,
11, 17).
This is another report of conservative treatment of endome-
trial carcinoma followed by successful pregnancy through
the IVF program. We believe that hysteroscopic examina-
tion during the infertility work up would be helpful not only
in the evaluation of abnormal findings of hysterosalpingog-
raphy but also of endometrial pathology in patients with
highly suspicion of endometrial disease due to prolonged
unopposed estrogen exposure.
We prescribed initially megestrol acetate, 600 mg daily
that was the highest dose of progestins ever reported, and
observed the regression of the endometrial carcinoma through
the complex hyperplasia without cellular atypia to atrophic
endometrim. And we agree with Kimmig et al. in that pro-
gestin treatment should be followed immediately by down-
regulatory therapy with GnRHa in order to prevent reinduc-
tion of the menstrual cycles and unnecessary prolonged expo-
sure to estrogens, and assisted reproductive technologies would
be helpful in women who wish to conceive.
In conclusion, we report a case of successful live birth
through the IVF program after conservative treatment of
endometrial cancer (stage I, grade 1). The fertility-preserv-
ing treatment is an option in endometrial cancer patients if
carefully selected, and assisted reproductive technologies
would be helpful.
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